Patient brochure for patients prescribed QUVIVIQ™ ▼ (daridorexant)

Download your printable PDF copy

Click on the button below to download the printable PDF of the patient brochure for patients prescribed QUVIVIQ™.

How can the QUVIVIQ™ Patient Brochure support your patients?

  1. Clear and concise information

    Simple overview of causes and symptoms of chronic insomnia – to aid full understanding of why QUVIVIQ™ has been prescribed

  2. Reassurance

    Straightforward insights into suggested biological causes of chronic insomnia, so patients know it’s not their fault, plus reassurance of how QUVIVIQ™ works differently to other hypnotics.

  3. Patient Engagement

    How patients can make the most of their treatment with QUVIVIQ™: simple reminder techniques and the importance of sleep hygiene

Download will open in a new window.

Patient support material from Idorsia Pharmaceuticals UK Ltd.

QUVIVIQ™ (daridorexant) is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.1

References

1 – QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics. 

2 – Roch C, et al. Psychopharmacology. 2021; 238(10): 2693–2708.

3 – NICE Clinical Knowledge Summary (CKS) Insomnia: Scenario: Managing long-term insomnia (more than 3 months duration). Available at: https://cks.nice.org.uk/topics/insomnia/management/managing-insomnia/. Accessed March 2026.

4 – Mignot E, et al. Lancet Neurol. 2022; 21(2): 125–139.

This information is intended for UK healthcare professionals.

Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google play or Apple App store. Adverse events should also be reported to ds.safety.uk@idorsia.com.

UK-DA-00784
| Date of preparation: March 2026
Copyright © 2026 Idorsia Pharmaceuticals Ltd

Related posts

Symposia Replay Hub

Promotional material from Idorsia Pharmaceuticals UK Ltd.

Beyond sleepless nights: managing chronic insomnia in adults in primary care

Promotional material from Idorsia Pharmaceuticals UK Ltd.

Pulse 365 Virtual Spotlight Sessions

Promotional material from Idorsia Pharmaceuticals UK Ltd.

Self-led e-learning programme: Understanding chronic insomnia

Promotional material from Idorsia Pharmaceuticals UK Ltd.

Mechanism of action of QUVIVIQ™▼ (daridorexant)

Promotional material from Idorsia Pharmaceuticals UK Ltd.

Mechanism of chronic insomnia

Promotional material from Idorsia Pharmaceuticals UK Ltd.

Treatment algorithm for adults with chronic insomnia

Promotional material from Idorsia Pharmaceuticals UK Ltd.

Vodcast series: Insomnia Uncovered

Promotional material from Idorsia Pharmaceuticals UK Ltd.

Overactive wake signalling as a possible cause of chronic insomnia

Promotional material from Idorsia Pharmaceuticals UK Ltd.

Insomnia conversation starter

Patient support material from Idorsia Pharmaceuticals UK Ltd.

Other readers liked

...Less than 1 hour

Symposia Replay Hub

Replay Video
Access recordings from Idorsia-sponsored symposia featuring healthcare professionals discussing clinical data and practical considerations for QUVIVIQ™▼ (daridorexant) in chronic insomnia.

Promotional material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-01145
| Date of preparation: February 2026
...Less than 1 hour

Beyond sleepless nights: managing chronic insomnia in adults in primary care

Replay CPD hours Video
Catch up on our CPD-accredited webinar series in collaboration with MIMS Learning. Our expert speakers explore the impact of chronic insomnia in diverse patient populations, discuss diagnostic approaches and share real-life experiences with patients.

Promotional material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-01116
| Date of preparation: February 2026
...Less than 1 hour

Pulse 365 Virtual Spotlight Sessions

Replay Video
Access recordings from Pulse 365 Virtual events where Idorsia sponsors educational Spotlight sessions. These 45-minute sessions feature experts discussing insomnia, management of chronic insomnia, and real-life patient experiences with QUVIVIQ™▼ (daridorexant).

Promotional material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-01143
| Date of preparation: March 2026
...Less than 1 hour

Self-led e-learning programme: Understanding chronic insomnia

E-learning course
This series of 6 20-minute modules has been reviewed by an expert faculty in sleep and insomnia, to support you in learning about chronic insomnia and the treatment options available for your patients.

Promotional material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-00740
| Date of preparation: April 2025
...Less than 5 min.

Mechanism of action of QUVIVIQ™▼ (daridorexant)

Video
Watch to discover the mechanism of action of QUVIVIQ™, and how it can reduce overactive wake signalling in patients with chronic insomnia.

Promotional material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-00789
| Date of preparation: February 2026
...Less than 5 min.

Mechanism of chronic insomnia

Video
Watch to discover the role of overactive wake signalling as a possible cause of chronic insomnia.

Promotional material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-00790
| Date of preparation: February 2026
...Less than 5 min.

Treatment algorithm for adults with chronic insomnia

Downloadable document
Developed by Idorsia Pharmaceuticals Ltd, in consultation with the authors, utilising the BMC Primary Care publication “Assessment and management of chronic insomnia disorder: an algorithm for primary care physicians” Selsick et al. BMC Primary Care (2024) 25:138

Promotional material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-00792
| Date of preparation: March 2026
...Less than 15 min.

Vodcast series: Insomnia Uncovered

Vodcast Video
Join Dr Allie Hare, consultant in sleep medicine in London, and Dr Cameron Livingston, a GP specialising in sleep in Glasgow, over a series of 6 vodcasts, as they discuss insomnia, its impact, diagnosis and treatment.

Promotional material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-00788
| Date of preparation: March 2026
...Less than 5 min.

Overactive wake signalling as a possible cause of chronic insomnia

Video
Watch this short presentation by Professor Dr. med. G. Hajak as he provides a concise introduction to the role of overactive wake signalling as a possible cause for chronic insomnia.

Promotional material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-00786
| Date of preparation: February 2026
...Less than 5 min.

Insomnia conversation starter

Downloadable document
This interactive questionnaire is designed to support your consultation with patients, helping to identify patients’ sleep concerns.

Patient support material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-00785
| Date of preparation: March 2026

Gain access to resources on chronic insomnia

Subscribe to get priority updates  and access to videos, data and patient resources, plus details about us and our offerings.

Register and stay up to date with the latest news about QUVIVIQ™▼ (daridorexant), chronic insomnia and sleep science. By registering and ticking this box you are confirming you have read and agreed to the Informed Consent and Privacy Policy and you herewith consent to the processing of your personal data in line therewith.

Discover how QUVIVIQ™ (daridorexant) is different to other hypnotics1,2:

Works differently1,2

Is taken differently1,3

Is experienced differently1,4

Book an appointment

One of our product specialists would be happy to answer your questions.

References

1 – QUVIVIQ™ Idorsia Pharmaceuticals LTD, summary of product characteristics. Last updated: September 2024. 2 – Roch C, et al. Psychopharmacology. 2021; 238(10): 2693–2708. 3 – Mignot E, et al. Lancet Neurol. 2022; 21(2): 125–139. 4 –. Robbins R, et al. Front Sleep. 2022; 1: 935228. 5 – Di Marco T, et al. CNS Drugs. 2023; 37(7): 639–653. 6 – Kunz D, et al. CNS Drugs. 2022; 37(1): 93–106.

 

UK-DA-XXXXX | Date of preparation: February 2025

Copyright © 2026 Idorsia Pharmaceuticals Ltd

Welcome to the Idorsia UK
Healthcare Professional Portal

This information is intended for UK Healthcare Professionals only.

By entering this site you are confirming that you are a UK Healthcare Professional.

UK-DA-00217 | Date of preparation: February 2026

Copyright ©2026 Idorsia Pharmaceuticals Ltd
Welcome back!

Please complete the form below to sign in.

You don’t have an account? 

You are now leaving
pro.idorsia.uk

You will now be redirected to an independent third party site that is maintained outside of this website, where all Idorsia Pharmaceuticals Ltd UK’s medicines can be found: the electronic Medicines Compendium (eMC)

UK-DA-00439 | Date of preparation: February 2026

Copyright ©2026 Idorsia Pharmaceuticals Ltd

Your resource is ready to download.

Providing your details is optional, but enables us to share future updates and resources that may be of interest to you.

Download will open in a new window.

Register and stay up to date with the latest news about QUVIVIQ™▼ (daridorexant), chronic insomnia and sleep science. By registering and ticking this box you are confirming you have read and agreed to the Informed Consent and Privacy Policy and you herewith consent to the processing of your personal data in line therewith.

You are now leaving
pro.idorsia.uk

You are now leaving pro.idorsia.uk. You will now be redirected to an independent third-party site that is maintained outside of this website.

You are now leaving pro.idorsia.uk. The linked website provides helpful information if you are having trouble sleeping. It is neither owned or controlled by Idorsia Pharmaceuticals Ltd. Idorsia accepts no responsibility for the content or services of the linked site.

UK-DA-00445 | Date of preparation: Februrary 2026

Copyright ©2026 Idorsia Pharmaceuticals Ltd

Confirming your contact information and preferences means that you agree that we, Idorsia, manage your personal data in our Client Relationship Management system to document, customise, plan, and conduct our interactions with you and, to analyse and segment your interactions, interests, preferences, and scientific activities in order to interact with you in a way we think is most relevant to you.

It also means that you agree that we will send you Idorsia standard or personalised medical, company or product related information and material via email based on your choices and on what we think is of interest to you. You further consent that we process your personal data for this.

For more information about us, our processing of your personal data and your rights, please see our Privacy Notice.

Create an account
Access our in-depth e-learning resources on chronic insomnia
Title *
First name *
Last name *
Professional email *
Password *
Specialty *
Professional registration number *

You already have an account? 

Gain access to resources on chronic insomnia​

Register to get access to: